Mary Nnah
The Founder and Managing Director of Fidson Healthcare Plc., Dr. Fidelis Ayebae, has reaffirmed the company’s intention to retain its position as the leading pharmaceutical manufacturing company in Nigeria despite the very challenging business environment presently.
Speaking during the Annual General Meeting held in Lagos recently, Ayebae attributed the impressive performance of the company to the sustained support, trust, and interest of the company’s stakeholders and loyal customers.
He stressed that despite the very challenging business environment, the company will continue to strengthen its internal control mechanisms and invest in the next generation of leaders to sustain its excellent performance and embed its corporate culture which ensures the company’s profitability while adding value to lives.
“Given the company’s rapid expansion, penchant for strategic partnerships and workforce empowerment, we believe that this initiative will deliver the desired stability that will propel the company to its next phase of growth, relevance and dominance,” he added.
“Since inception, the success of our business has been dependent on our customers’ trust and continued patronage of our brands, most especially as an indigenous pharmaceutical company in a highly competitive market.
This sustained trust and support has been the driving force for our relentless commitment to delivering excellence in all our operations. This in turn has yielded great returns, served as a catalyst for business expansion and crystalised our position as the industry’s leader,” he noted further.
It was also revealed during the AGM that shareholders of Fidson Healthcare Plc will receive a dividend of 55 kobo per share for the year ending 31 December 2022.
The shareholders unanimously approved this at the event where it was also expressed that the dividend represents a 10 per cent increase, an improvement on the 50 kobo per share paid in the 2021 financial year.
Fidson Healthcare PLC is expanding its pharmaceutical production capacity to meet Nigeria’s growing demand for critical therapeutic area drugs as well as other West African countries. The company boasts of a remarkable portfolio of over 350 NAFDAC-registered brands and is undertaking the expansion project at its World Health Organisation Good Manufacturing Practice (WHO-CGMP) compliant facility in Ota, Nigeria.
In its pursuit of excellence in pharmaceutical manufacturing in Sub-Saharan Africa, Fidson has made significant investments in state-of-the-art machinery and expertise. The expansion project has progressed seamlessly, leading to successful partnerships with renowned global industry leaders such as GSK and Bayer for contract manufacturing.
